Abstract
Chlamydia trachomatis infection (chlamydia) is the most prevalent sexually transmitted bacterial infection and causes significant reproductive morbidity in women. Little is known about how immunity to chlamydia develops in women, though animal models of chlamydia indicate that T-helper type 1 (Th1) responses are important for chlamydia clearance and protective immunity, whereas T-helper type 2 (Th2) responses are associated with persisting infection. In chlamydia-infected women, whether the predominant immune response is Th1- or Th2-polarizing remains controversial. To determine the cytokine profiles elicited by peripheral blood mononuclear cells (PBMCs) from chlamydia-infected women, we stimulated PBMCs with C. trachomatis elementary bodies and recombinant C. trachomatis Pgp3 and measured supernatant levels of select cytokines spanning Th1- and Th2-polarizing responses. We found that stimulated PBMCs from chlamydia-infected women secreted cytokines that indicate strong Th1-polarizing responses, especially interferon-gamma, whereas Th2-polarizing cytokines were expressed at significantly lower levels. In chlamydia-infected women, the predominant cytokine responses elicited on stimulation of PBMCs with C. trachomatis antigens were Th1-polarizing, with interferon-gamma as the predominant cytokine.
INTRODUCTION
Chlamydia trachomatis (Ct) causes “chlamydia”, the most prevalent bacterial sexually transmitted infection (STI) worldwide [1], and is associated with significant reproductive morbidity in women [2]. A Ct vaccine is urgently needed to curb rising Ct rates, but the knowledge gap in our understanding of systemic immune responses in humans hinders its development [3]. The majority of our knowledge of immune responses to chlamydia has been obtained using challenge studies in animal models of urogenital chlamydia. Animal models demonstrate that T-helper type 1 (Th1) cells strongly correlate with immunity against chlamydia re-challenge, although the T-cell type responsible appears to differ by species [4]. The Th1 cytokine IFN-γ plays a major role in protective immunity, although other cytokines are likely contributory [5]. One potential cytokine that may act in synergy with IFN-γ is TNF-α, which has been shown to have anti-chlamydial properties, including strongly accentuating the inhibitory effect of IFN-γ on Ct growth in vitro [6]. Further, in mice, the presence of CD4+ T-cells producing both TNF-α and IFN-γ correlated with protection against chlamydia challenge [7], which highlights the importance of studying multiple cytokines to determine the contribution of different cytokine profiles in Ct infection.
In humans, studies of immune responses to chlamydia are limited and the dominant Th response to natural Ct infection remains insufficiently understood. A small study of adolescent women demonstrated that IFN-γ production by CD4+ T-cells trended towards a reduced risk for reinfection [8]. Another study showed an increased in the frequency of IFN-γ-producing CD4+ T-cells in women without incident CT infection compared to women with CT infection [9]. Further support for the protective role of IFN-γ comes from an immunoepidemiologic study of commercial sex workers that showed a reduced risk for incident Ct infection was associated with the Th1 cytokine IFN-γ and also the Th2 cytokine IL-13 [10]. Another study found that the predominant peripheral blood mononuclear cell (PBMC) response in Ct-infected women was polarized towards Th2, characterized by IL-4 production [11]. Given the conflicting findings from these studies, the predominant response in Ct-infected women remains to be fully elucidated.
We previously showed in a cohort of Ct-infected women that TNF-a is the predominant Th1 cytokine produced by peripheral CD4+ T-cells from chlamydia-infected women, not IFN-γ, with approximately one third of TNF-γ-positive T-cells co-expressing either IFN-γ or IL-2 [12]. Surprisingly, IFN-γ responses were infrequent in that study, though our analysis was limited to CD4+ and CD8+ T-cells and only evaluated the Th1 cytokines IFN-γ, TNF-α, and IL-2 by intracellular cytokine staining. In this pilot study of cytokine responses in Ct-infected women, we expand our previous cytokine evaluation to include the Th1-polarizing cytokine IL-12 and Th2 cytokines, and we used multiplex cytokine analysis to measure cytokine levels directly from supernatants collected from PBMCs stimulated with Ct antigens. The primary study objective was to expand our understanding of which Th cytokine profile (Th1 vs. Th2) is dominant in stimulated PBMCs from Ct-infected women and whether specific cytokines within a Th profile contributed more than others.
MATERIALS AND METHODS
Study Population and Procedures.
In this study, we evaluated cytokines in CT-infected women at an enrollment visit, which was part an ongoing longitudinal study that has been previously described [12]. Briefly, females ≥16 years of age returning to a STD clinic for treatment of a positive screening Ct nucleic acid amplification test were enrolled. At enrollment, participants were interviewed and blood was collected for isolation of PBMCs. All participants received azithromycin 1g for Ct treatment. The study was approved by the University of Alabama at Birmingham (UAB) Institutional Review Board and the Jefferson County Department of Health.
PBMC Isolation.
PBMCs were isolated at the UAB Center for Clinical and Translational Sciences Specimen Processing and Analytical Nexus by centrifugation through lymphocyte separation medium (Mediatech, Inc, Manassas, VA). PBMCs were frozen in 1mL aliquots in 90% FBS+10% DMSO and cryopreserved in liquid nitrogen until used for immunological studies.
Stimulation Assays.
Thawed PBMCs were rested overnight and then 1×105 cells/well were added to a flat-bottom 96-well culture plate in RPMI-10 media (RPMI 1640 medium containing 10% human AB serum, penicillin/streptomycin [50 U/mL], HEPES [25 mM] and L-glutamine [2mM]) in the presence of Ct antigen and 10U/ml IL-2 incubated for 72 hours at 37°C in 5% CO2. After 72 hours, the cells were removed by centrifugation and the supernatant was stored at −80°C. Ct antigens used were: recombinant Ct Pgp3 (5 μg/ml, Biorbyt, San Francisco, CA), formalin-fixed Ct elementary bodies (4 μg/ml, EB, pooled serotypes D, F and J; obtained from Dr. Richard Morrison from the University of Arkansas for Medical Sciences, Little Rock, AR), and phytohemagglutinin (10 μg/ml, PHA) as the positive control. RPMI-10 was used to determine background cytokine responses.
Multiplex Cytokine Assay.
Cytokines were measured using a validated multiplex cytokine assay, V-PLEX (Meso Scale Discovery [MSD], Rockville, MD), according to the manufacturer’s instructions. Briefly, supernatants from PMBC stimulations were added in triplicate to 96-well V-PLEX plates and incubated on a rotary shaker for 2 hours at room temperature. The plates were then washed, cytokine-specific secondary antibodies (MSD, Rockville, MD) added, incubated for 90 minutes, washed, and read using a V-PLEX plate reader. A serial dilution of known cytokine standards was used to calculate the supernatant cytokine concentrations using MSD Discovery Workbench software (v4.0, MSD, Rockville, MD), after subtracting the background (blank wells). Supernatant cytokine concentrations are reported as pg/ml. Cytokine concentrations that were below the level of detection were replaced with the lowest measurable value.
Statistical analysis.
Descriptive statistics were used to summarize demographical and clinical characteristics. Antigen differences in frequencies of positive cytokine responses (defined as >2 standard deviations above the mean background [unstimulated] supernatant cytokine level) were evaluated by McNemar’s chi-square test. For the quantitative analysis of positive cytokine responses, log10-transformed cytokine levels were evaluated with mixed model analyses of variance with antigen as a main effect and participant as a random effect, which accounted for clustering of data within individual participants. Only cytokines with ≥5 positive responses were analyzed. Differences were considered significant at a P-value <0.05. Analyses were performed with SAS software, version 9.3 (SAS Institute, Cary, NC).
RESULTS
Seventy-seven chlamydia-infected women were included in this study (Table 1). The median age was 22 (range 16 – 38), 96% were African American and 99% non-Hispanic. 38% used hormonal contraception and the median number of sex partners in the last 3 months was one (range 1 – 9). 51% of women had a prior history of chlamydia (based on self-report or review of prior Ct test results). 56% of women were asymptomatic on enrollment, and co-infections present included bacterial vaginosis (in 23%), trichomoniasis (3%), and vulvovaginal candidiasis (14%).
Table 1.
Participant Characteristics, N (%) | |
---|---|
Median age (range) | 22 (16–38) |
Race | |
African American | 74 (96%) |
Caucasian | 3 (4%) |
Ethnicity | |
Non-Hispanic | 76 (99%) |
Hispanic | 1 (1%) |
Hormonal contraception* | 29 (38%) |
Median prior sex partners Last 3 mo. (range)* | 1 (1–9) |
Prior Chlamydia* | 39 (51%) |
Asymptomatic | 43 (56%) |
Co-Infections | |
HIV infection | Excluded |
Gonorrhea | Excluded |
Bacterial vaginosis | 18 (23%) |
Trichomoniasis | 2 (3%) |
Candidiasis | 11 (14%) |
Data missing for one participant
Ct antigen stimulated PBMCs from the majority of Ct-infected women secreted the Th1-polarizing cytokines IFN-g, TNF-α, and IL-12.
As shown in Figure 1A, the majority of women had positive Th1-polarizing IFN-g, TNF-α, and IL-12 responses and Th2 IL-10 responses to either Pgp3 or EB. Only one woman (1.2%) had a positive IL-4 response to Pgp3; all women had negative IL-4 responses to EB. Less than 10% of women had positive IL-13 responses. Overall, compared to Pgp3, EB-stimulated PBMCs were significantly more likely to elicit cytokine-positive responses.
Th1-polarizing cytokines were the dominant response by stimulated PBMCs in Ct-infected women.
Among the positive cytokine responses, the highest levels of cytokines were seen with the Th1-polarizing cytokines IFN-γ and TNF-α, which were significantly elevated above background levels (Figure 1B). Figure 1C shows cytokine levels for each antigen after subtracting the background (unstimulated cells). We also found differences in cytokine levels based on the Ct antigen used in the PBMC stimulation. IFN-γ had the highest levels of all cytokines studied, and the IFN-γ level produced in response to EB stimulation was significantly higher than to Pgp3 (median 171,166 pg/ml vs 39,248 pg/ml, respectively, P <0.001). Conversely for TNF-α, Pgp3-stimulated cells produced higher TNF-α levels than EB (2,343 pg/ml vs 1,350 pg/ml, respectively, P = 0.002). Although the majority of women generated positive IL-12 responses, the magnitude of IL-12 levels were low with the response to EB slightly higher than Pgp3 (3 pg/ml vs 1 pg/ml, P = 0.0001).
Th2 cytokines were produced at lower levels by stimulated PBMCs than the Th1 cytokines IFN-γ and TNF-α. The single positive IL-4 response was ≤0.01 pg/ml. IL-10 production was the highest of the Th2 cytokines, with levels produced to both Ct antigens of approximately 43 pg/ml. IL-13 responses were infrequent but, when present, were approximately 15 pg/ml. IL-10 or IL-13 responses did not differ by antigen.
Given the association of IFN-γ with protection against chlamydia in animal model studies and several human studies, we then assessed for any correlation between the frequency or magnitude of secreted IFN-γ and age, presence of symptoms, a prior history of chlamydia, number of partners in the last 3 months, use of hormonal contraception, and presence of co-infections. None of these factors were found to be correlated with either the frequency or magnitude of the IFN-γ response (data not shown).
DISCUSSION
Our study demonstrated that, in general, Th1-polarizing cytokine responses (especially IFN-γ and TNF-α) were produced at a higher frequency and magnitude than Th2-polarizing responses in stimulated PBMCs from Ct-infected women. Of the Th1-polarizing cytokines produced, levels were highest for IFN-γ, followed by TNF-α; IL-12 production was minimal. IFN-γ levels were highest when stimulated with EB, compared to Pgp3, which suggests that cytokine levels are related, in part, to antigen specificity (more antigens are present on the EB surface compared to the single recombinant antigen Pgp3). Given our previous finding that TNF-α, not IFN-γ, was the predominant cytokine produced by stimulated CD4+ T-cells [12], our current study findings suggest that in some Ct-infected individuals, there may be a significant contribution by other cell types to IFN-γ production, possibly natural killer (NK) cells. This hypothesis is further supported by a prior study demonstrating that Ct EB-stimulated PBMCs had high levels of IFN-γ production by NK cells [13]. Interestingly, another study demonstrated that NK cell function (including IFN-γ production) was impaired in some Ct-infected humans [14]. Together, these findings suggest that NK cells may contribute to IFN-γ production in some, but not all, Ct-infected individuals and warrants further investigation.
In our study, positive Th2 cytokines were both infrequent and secreted at low levels. Our results are consistent with a previous study that found IL-4 and IL-10 mRNA was produced at significantly lower levels than IFN-γ on stimulation with EB [15]. Our results appear discordant with the study by Vicetti Miguel et al., which concluded that stimulated PBMCs from Ct-infected women are primarily Th2-polarized [11]. An important distinction is that their study used intracellular cytokine staining to report a high frequency of IL-4-positive CD3+ proliferating cells, while our study objective was not limited to replicating CD3+ cells, but instead focused on measuring the increase in secreted cytokines (including IL-4) from stimulated PBMCs. Also, the PBMC stimulation length was different (48 hours in their study vs 72 hours in our study), which may also contribute to differences in cytokine levels.
Interestingly, the secretion of the Th1-polarizing cytokine IL-12 was low in our study which, combined with the high levels of IFN-γ produced in Ct-infected women, suggests that a significant contribution of IFN-γ production may occur through an IL-12-independent mechanism, as has been reported to occur with other intracellular pathogens [16] and may be NK cell-mediated [17]. This implies that Th1 polarization may occur through multiple mechanisms and warrants further study into how specific cell types contribute to Th1 polarized IFN-γ production.
Our study has strengths and weaknesses. To our knowledge, this is the largest study to date of Th1- and Th2-polarizing cytokine responses produced by PBMCs from Ct-infected humans. We also used a recombinant Ct-specific protein (Pgp3) to address potential concerns about cytokine responses being confounded by cross-reactivity of Ct EBs (e.g. from Ct HSP60, etc.) or non-specific responses (e.g., from Ct LPS). We acknowledge that African Americans were over-represented in our study, which could limit generalizability of findings. We also used whole PBMCs (without monocyte depletion) in our assays and the contribution of non-lymphoid cells (i.e. NK cells, monocytes) to total IFN-γ production remains unknown. Also, cytokine studies using stimulated PBMCs in vitro may not completely reflect cytokine production in the mucosal environment. Future studies involving depletion of specific cell-populations in both Ct-infected and Ct-negative women will be important in defining the contribution of Th1-polarizing cytokine production by specific IFN-γ-producing populations (e.g. NK cells).
In conclusion, we showed that stimulated PBMCs from Ct-infected women produce predominantly Th1-polarizing cytokines on exposure to Ct antigens Pgp3 and EB, but not Th2-polarizing cytokines. Future studies that investigate the contribution of individual cell populations to Th1 cytokine production are warranted.
ACKNOWLEDGMENTS
We thank Hanne Harbison and Cynthia Poore for their assistance in collection of specimens and clinical data for the study. We thank Shelly Lensing for her assistance with statistical analyses. We thank Richard Morrison for providing the C. trachomatis elementary bodies used in our immunological assays.
FUNDING INFORMATION
This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (award R01AI093692 to W.M.G.) and by the National Center for Advancing Translational Sciences of the National Institutes of Health (award UL1TR001417). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
REFERENCES
- [1].W.H. Organization, WHO guidelines for the treatment of Chlamydia trachomatis, 2016. [PubMed]
- [2].Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis 2010; 201 Suppl 2: S134–55. [DOI] [PubMed] [Google Scholar]
- [3].Geisler WM. Duration of untreated, uncomplicated Chlamydia trachomatis genital infection and factors associated with chlamydia resolution: a review of human studies. J Infect Dis 2010; 201 Suppl 2: S104–13. [DOI] [PubMed] [Google Scholar]
- [4].Rank RG, Whittum Hudson JA. Protective immunity to chlamydial genital infection: evidence from animal studies., J Infect Dis 2010; 201 Suppl 2: S168–77. [DOI] [PubMed] [Google Scholar]
- [5].Ito JI, Lyons JM. Role of gamma interferon in controlling murine chlamydial genital tract infection. Infect Immun 1999; 67(10): 5518–5521. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [6].Shemer-Avni Y, Wallach D, Sarov I. Inhibition of Chlamydia trachomatis growth by recombinant tumor necrosis factor. Infect Immun 1988; 56(9): 2503–2506. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [7].Yu H, Karunakaran KP, Kelly I, Shen C, Jiang X, Foster LJ, Brunham RC. Immunization with live and dead Chlamydia muridarum induces different levels of protective immunity in a murine genital tract model: correlation with MHC class II peptide presentation and multifunctional Th1 cells. J Immunol 2011; 186(6): 3615–3621. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [8].Barral R, Desai R, Zheng X, Frazer LC, Sucato GS, Haggerty CL, O’Connell CM, Zurenski MA, Darville T. Frequency of Chlamydia trachomatis-specific T cell interferon-γ and interleukin-17 responses in CD4-enriched peripheral blood mononuclear cells of sexually active adolescent females. J Repro Immunol 2014; 103: 29–37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [9].Russell AN, Zheng X, O’Connell CM, Wiesenfeld HC, Hillier SL, Taylor BD, Picard MD, Flechtner JB, Zhong W, Frazer LC, Darville T. Identification of Chlamydia trachomatis antigens recognized by T cells from highly exposed women who limit or resist genital tract infection. J Infect Dis 2016; 214(12): 1884–1892. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [10].Cohen CR, Koochesfahani KM, Meier AS, Shen C, Karunakaran K, Ondondo B, Kinyari T, Mugo NR, Nguti R, Brunham RC. Immunoepidemiologic profile of Chlamydia trachomatis infection: importance of heat-shock protein 60 and interferon-γ, J infect Dis 2005; 192(4): 591–599. [DOI] [PubMed] [Google Scholar]
- [11].Vicetti Miguel RD, Harvey SAK, LaFramboise WA, Reighard SD, Matthews DB, Cherpes TL. Human female genital tract infection by the obligate intracellular bacterium Chlamydia trachomatis elicits robust type 2 Immunity. PLoS ONE 2013; 8(3): e58565. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [12].Jordan SJ, Gupta K, Ogendi BMO, Bakshi RK, Kapil R, Press CG, Sabbaj S, Lee JY, Geisler WM. The predominant CD4(+) Th1 cytokine elicited to Chlamydia trachomatis infection in women Is tumor necrosis factor alpha and not interferon gamma. Clin Vaccine Immunol 2017; CVI 24(4): e00010–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [13].Hook CE, Telyatnikova N, Goodall JC, Braud VM, Carmichael AJ, Wills MR, Gaston JSH. Effects of Chlamydia trachomatis infection on the expression of natural killer (NK) cell ligands and susceptibility to NK cell lysis. Clin Exp Immunol 2004; 138(1): 54–60. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [14].Mavoungou E, Poaty-Mavoungou V, Touré FS, Sall A, Delicat A, Yaba P, Mandeme Y, Nabias R, Lansoud-Soukate J. Impairment of natural killer cell activity in Chlamydia trachomatis infected individuals. Trop Med Int Health 1999; 4(11): 719–727. [DOI] [PubMed] [Google Scholar]
- [15].Gupta R, Srivastava P, Vardhan H, Salhan S, Mittal A. Host immune responses to chlamydial inclusion membrane proteins B and C in Chlamydia trachomatis infected women with or without fertility disorders., Repro Biol Endo 2009; 7: 38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [16].John B, Rajagopal D, Pashine A, Rath S, George A, Bal V. Role of IL-12-independent and IL-12-dependent pathways in regulating generation of the IFN-γ component of T cell responses to Salmonella typhimurium. J Immunol 2002; 169: 2545–2552. [DOI] [PubMed] [Google Scholar]
- [17].Lu HZ, Zhu AY, Chen Y, Tang J, Li BQ. Lower concentrations of methyl-beta-cyclodextrin combined with interleukin-2 can preferentially induce activation and proliferation of natural killer cells in human peripheral blood. Hum Immunol 2011; 72(7): 538–46. [DOI] [PubMed] [Google Scholar]